Triple-negative breast cancers may be vulnerable to drugs that attack the proteasome, a cellular structure that acts as the cell’s waste disposal, breaking down damaged or unneeded proteins, according to a new paper in Cancer Cell.
In lab tests, researchers selectively “turned off” genes throughout the genomes of triple-negative tumor cells. When turned off, the cells die.
These data suggest that triple-negative breast cancers may respond to treatment with drugs similar to bortezomib (Velcade), which is used in multiple myeloma.
• Read more about TNBC in my book, Surviving Triple-Negative Breast Cancer.